Effectiveness of PCSK9 inhibitors versus statins in type 2 diabetes and dyslipidemia: a propensity-matched study
Among patients with T2D and dyslipidemia, PCSK9i use was associated with reduced incidences of cardiovascular and renal events and all-cause mortality compared to statin therapy. These findings support the promising role of PCSK9is in high-risk diabetic populations.
Authors
- Tinghui Liu (ORCID: https://orcid.org/0009-0001-9634-3715)
- Po‐Yu Huang (ORCID: https://orcid.org/0000-0002-8682-1322)
- Tsung Yu (ORCID: https://orcid.org/0000-0002-5773-3665)
- Wan‐Hsuan Hsu (ORCID: https://orcid.org/0000-0002-2517-1792)
- Ya‐Wen Tsai (ORCID: https://orcid.org/0000-0003-4630-3923)
- Jheng‐Yan Wu (ORCID: https://orcid.org/0000-0002-3290-1909)
- Yu Min Lin (ORCID: https://orcid.org/0009-0007-5425-7492)
- Chih-Cheng Lai
- Michael L. Chuang
Institutions
- National Sun Yat-sen University (TW)
- Chi Mei Medical Center (TW)
- National Cheng Kung University (TW)
Publication Details
- Journal
- Frontiers in Endocrinology
- Published
- 2025-11-19
- DOI
- https://doi.org/10.3389/fendo.2025.1709009
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00